|
Market Cap (19-May) $4,758,880 (1,313th) |
Close (30-Jun) $1.51 |
Volume (30-Jun) 12,937 |
Shortsold (8-Aug) 2,108 (0.02%) (508th) |
|
52w High $1.09 |
52w Low $0.280 |
P/E - |
EPS -0.42 |
ZLD released this announcement to the ASX on 16 September 2022, 10:32. The announcement is not marked as price sensitive, and is 78 page(s) in length and 1.97MB in size.
You can view all announcements from ZLD and see how they appear on a price chart on the announcements page.
At the date of this announcement, ZLD was 0.031% short sold according to ASIC data. It was ranked the 485th most shorted stock on the ASX. It remains ranked 508th as of the latest reported data (08 August 2024).
| Other Recent Announcements from ZLD | |
|---|---|
| Amendment to ASX announcement - Zelira's diabetic nerve pai | 8 June 2023, 9:47 |
| Initial Director's Interest Notice | 1 June 2023, 15:29 |
| Final Director's Interest Notice | 1 June 2023, 15:27 |
| Annual Report to shareholders | 16 September 2022, 10:32 |
| ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled | 15 September 2022, 8:26 |
| Partial Receipt of Health House Loan | 8 September 2022, 9:23 |
| Investor Briefing Webinar Presentation | 7 September 2022, 9:53 |
You must be logged in to post a reply.
Zelira Therapeutics 